All News

The Pharmacy Times® Future of Pharmacy Resource Center is a comprehensive source on the evolution of the pharmacy profession and the growing roles of pharmacists

The Future of Pharmacy initiative is telling the story of where the profession has been and where it is headed.

Sonidegib is a biphenyl carboxamide that blocks the signaling in the hedgehog pathway.

The first step to reducing recurrent C. difficile infections is prevention.

Paul Feuerstadt, MD, FACG, AGAF, discussed the investigative C. difficile treatment RBX2660 and how it impacts time to recurrence.

Nearly 63% of newly diagnosed patients have advanced colorectal cancer, which requires more aggressive treatment and reduces the associated 5-year survival rate.

Ashwagandha KSM-66 (Anxiety & Stress Relief) from Nature’s Bounty is indicated to help manage occasional stress and anxiety.

Many patients with heart failure are hesitant to receive the COVID-19 vaccine due to the fear of myocarditis.

Findings from a study highlight the efficacy and safety of bulevirtide for the treatment of chronic hepatitis delta virus.

Livalo is an HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in adults with primary hyperlipidemia or mixed dyslipidemia.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses the importance of putting precision medicine programs into oncology practices with pharmacists leading the way.

Pharmacy Times will be covering the 2022 ATOPP Summit live in San Diego, CA.

Amy Woodard, PharmD, BCOP, the steering committee co-chair of the 2022 ATOPP Summit, highlights key topics and discussions at the in-person summit in July in San Diego, CA.

Pharmacy Times will be covering McKesson ideaShare 2022 live in Washington, DC, from July 7 through 10.

This month's product news features acyclovir oral suspension, vigabatrin oral solution, and budesonide and formoterol bumarate dihydrate inhalation aerosol.

As we learn more about inflammatory syndromes, we may get better at using laboratory tests to identify and isolate the actual cellular and chemical processes that drive them.

Paul Feuerstadt, MD, FACG, AGAF, discussed research into the novel C. difficile treatment RBX2660 and what investigators have found about its efficacy in key subgroup analyses.

How would you respond to these patients questions?

Metformin has been shown to decrease pro-inflammatory cytokines that appear to improve the immune response to tumor cells and improve the efficacy of immunotherapy.

Rivaroxaban is the only FDA-approved anticoagulant used in patients with peripheral artery disease and coronary artery disease.

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses some common challenges hematology oncology pharmacists face in the field during their pursuit of professional growth and development.

There have been many changes made in the LGBTQ+ community for the better, but there is still work to do be done, especially as a health care professional.

Median radiographic progression-free survival was 24.8 months for olaparib plus abiraterone, compared to 16.6 months in the abiraterone arm.

With many ambiguous policies, pharmacists should refer to their State Boards of Pharmacy for guidance and should consider HIPAA implications.

The approval eliminates the need for traditional nitric oxide tanks in the hospital setting.

Cenobamate is a once daily anti-epileptic medication with a recommended maintenance dose of 200 mg once daily that can be prescribed as monotherapy or adjunctive therapy.

Brought to you by The Sassy Pharmacist

Companies, FDA caught unaware by surge in virus cases, leading to shortage of critical items.

The study included the BNT162b2 and CoronaVac vaccines, which are the only COVID-19 vaccines authorized for emergency use in Hong Kong.

Investigators also noted that Black, Hispanic, and Asian individuals were less likely than white individuals to undergo timely angiography and had minimal changes overtime.